James Mathers Sells 2,500 Shares of BioLife Solutions Inc (NASDAQ:BLFS) Stock

BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $16.33, for a total transaction of $40,825.00. Following the sale, the vice president now owns 19,884 shares in the company, valued at $324,705.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

James Mathers also recently made the following trade(s):

  • On Wednesday, November 27th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.27, for a total transaction of $40,675.00.
  • On Tuesday, November 12th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.69, for a total transaction of $41,725.00.
  • On Thursday, October 31st, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.89, for a total transaction of $42,225.00.
  • On Tuesday, October 29th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.31, for a total transaction of $43,275.00.
  • On Tuesday, October 15th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.06, for a total transaction of $40,150.00.
  • On Thursday, October 17th, James Mathers sold 2,693 shares of BioLife Solutions stock. The shares were sold at an average price of $16.42, for a total transaction of $44,219.06.
  • On Wednesday, October 2nd, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $15.78, for a total transaction of $39,450.00.
  • On Wednesday, September 18th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.95, for a total transaction of $52,375.00.
  • On Thursday, September 5th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.11, for a total transaction of $50,275.00.
  • On Tuesday, September 3rd, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.07, for a total transaction of $50,175.00.

BLFS opened at $16.75 on Monday. The firm’s fifty day moving average price is $16.46 and its two-hundred day moving average price is $17.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.49 and a quick ratio of 5.33. The company has a market capitalization of $342.57 million, a price-to-earnings ratio of 139.58, a P/E/G ratio of 20.94 and a beta of 1.33. BioLife Solutions Inc has a 1 year low of $9.15 and a 1 year high of $22.44.

Several large investors have recently modified their holdings of BLFS. JPMorgan Chase & Co. purchased a new position in shares of BioLife Solutions in the 2nd quarter worth about $30,000. Alpine Woods Capital Investors LLC bought a new stake in BioLife Solutions in the 2nd quarter valued at about $170,000. Morgan Stanley raised its stake in BioLife Solutions by 17.5% in the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after acquiring an additional 1,713 shares during the period. Menta Capital LLC bought a new stake in BioLife Solutions in the 2nd quarter valued at about $202,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of BioLife Solutions during the second quarter valued at about $283,000. 50.22% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on BLFS shares. Zacks Investment Research lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Monday, November 25th. BidaskClub upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Monday, November 25th. Oppenheimer assumed coverage on shares of BioLife Solutions in a report on Wednesday, November 20th. They set an “outperform” rating and a $22.00 price target for the company. ValuEngine upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Saturday, November 23rd. Finally, Northland Securities lifted their price objective on shares of BioLife Solutions from $18.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $19.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Story: How to Invest in Marijuana Stocks

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.